184
Participants
Start Date
July 10, 2020
Primary Completion Date
July 9, 2024
Study Completion Date
July 9, 2024
CC-90010
Specified dose on specified days
Temozolomide
Specified dose on specified days
Radiotherapy
Specified dose on specified days
Local Institution - 501, Copenhagen
Local Institution - 500, Odense
Local Institution - 503, Aalborg
Local Institution - 800, New York
Local Institution - 311, A Coruña
Local Institution - 202, Milan
Local Institution - 201, Milan
Local Institution - 304, Madrid
Local Institution - 301, Madrid
Local Institution - 300, Madrid
Local Institution - 310, Pamplona
Local Institution - 204, Padua
Local Institution - 312, Vigo
Local Institution - 200, Verona
Local Institution - 309, Seville
Local Institution - 305, Valencia
Local Institution - 703, Uppsala
Local Institution - 408, Leiden
Local Institution - 405, Amsterdam
Local Institution - 400, Rotterdam
Local Institution - 401, Utrecht
Local Institution - 600, Oslo
Local Institution - 306, Barcelona
Local Institution - 302, Barcelona
Local Institution - 303, Barcelona
Local Institution - 307, Hospitalet de Llobregat, Barcelona
Local Institution - 702, Gothenburg
Local Institution - 701, Lund
Local Institution - 700, Solna
Lead Sponsor
Celgene
INDUSTRY